1
|
Funes‐Ferrada R, Barrios‐Ruiz A, Yu Lee‐Mateus A, Johnson MM, Fernandez‐Bussy S, Abia‐Trujillo D. Long-term pneumatic stenting with positive expiratory pressure therapy for severe expiratory central airway collapse. Respirol Case Rep 2024; 12:e01367. [PMID: 38725709 PMCID: PMC11079437 DOI: 10.1002/rcr2.1367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Accepted: 04/28/2024] [Indexed: 05/12/2024] Open
Abstract
Expiratory central airway collapse (ECAC) comprising excessive central airway collapse (EDAC) and tracheobronchomalacia. Treatment is challenging for severe cases that are not candidates for surgical management. We report a case of severe ECAC successfully managed with continuous positive airway pressure (CPAP) therapy. A 75-year-old female patient status post right pneumonectomy, presented with chronic cough. Dynamic bronchoscopy evaluation showed severe EDAC which improved with intraprocedural noninvasive positive pressure (NIPPV) therapy. Due to patients' comorbidities, she was not a candidate to surgical tracheobronchoplasty. Therefore, we attempted pneumatic stenting with long-term CPAP therapy resulting in improvement of symptoms and functional capacity. The long-term efficacy of pneumatic stenting has not been clearly established yet. Literature review of management of ECAC with NIPPV consist primarily of case reports and there is only one clinical trial being conducted to assess the efficacy of CPAP therapy in ECAC. While NIPPV arises as a sufficient alternative for management of severe ECAC, larger scale studies are needed to prove the real efficacy of NIPPV in this setting.
Collapse
Affiliation(s)
| | - Alanna Barrios‐Ruiz
- Division of Pulmonary, Allergy, and Sleep MedicineMayo ClinicJacksonvilleFloridaUSA
| | | | - Margaret M. Johnson
- Division of Pulmonary, Allergy, and Sleep MedicineMayo ClinicJacksonvilleFloridaUSA
| | | | - David Abia‐Trujillo
- Division of Pulmonary, Allergy, and Sleep MedicineMayo ClinicJacksonvilleFloridaUSA
| |
Collapse
|
2
|
Yu Lee-Mateus A, Chandra NC, Johnson MM, Abia-Trujillo D, Reisenauer J, Fernandez-Bussy S. Robotic-Assisted Bronchoscopy Integrated with Three-Dimensional Fluoroscopy for Sampling Bilateral Pulmonary Nodules in a Single Procedure. Respiration 2023:1-5. [PMID: 37105143 DOI: 10.1159/000530234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 03/15/2023] [Indexed: 04/29/2023] Open
Abstract
Bronchoscopic biopsy of peripheral pulmonary nodules has evolved in recent years with the emergence of new technologies such as shape-sensing robotic-assisted bronchoscopy. The use of three-dimensional (3D) fluoroscopy for intraoperative visualization of the biopsy tool in relation to the target nodule aims to overcome computed tomography-to-body divergence encountered during the procedure and allows for more accurate sampling to improve adequacy and diagnostic performance. Until recently, the robotic-assisted navigation plan and 3D imaging function as separate systems. We present a case where intraoperative 3D fluoroscopy images were integrated to the robotic bronchoscopy navigation system, resulting in a single, dynamic, real-time 3D virtual plan showing readjusted paths toward the lesion displayed in the robotic bronchoscopy navigation system, allowing in this case, biopsying two bilateral pulmonary nodules, resulting in different diagnosis within the same endoscopic procedure.
Collapse
Affiliation(s)
| | - Nikitha C Chandra
- Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | - Margaret M Johnson
- Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | - David Abia-Trujillo
- Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | - Janani Reisenauer
- Department of Pulmonary Medicine and Thoracic Surgery, Mayo Clinic, Rochester, Minnesota, USA
| | | |
Collapse
|
3
|
Diaz‐Churion F, Yu Lee‐Mateus A, Abia‐Trujillo D, Johnson MM, Khoor A, Patel NM, Reisenauer J, Fernandez‐Bussy S. Real-time visualization of lung malignancy with needle-based confocal laser endomicroscopy during shape-sensing robotic-assisted bronchoscopy. Respirol Case Rep 2023; 11:e01092. [PMID: 36751399 PMCID: PMC9892892 DOI: 10.1002/rcr2.1092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 01/17/2023] [Indexed: 02/05/2023] Open
Abstract
Robotic-assisted bronchoscopy (RAB) improves endoscopic diagnostic yield of solitary pulmonary nodules (SPN). Needle-based confocal laser endomicroscopy (nCLE) is an emerging technology that allows high-resolution, in-vivo, real-time assessment of living tissues at a cellular and subcellular level. Their combined use has been scarcely reported. We used them simultaneously in three patients with SPNs. For each, the nodule was evaluated with nCLE and sampled for pathology, followed by mediastinal staging. Median age was 77 years (67% male). Median nodule minimum size was 1.8 cm and maximum was 2.1 cm. nCLE detected abnormal patterns suggestive of malignancy for all nodules and pathology confirmed primary lung adenocarcinomas in two patients and lung primary squamous cell carcinoma in the other. The combined use of RAB with nCLE may potentially enhance the differentiation of malignant cells in real-time and increase sample adequacy, accuracy, and diagnostic yield when biopsying a suspicious pulmonary lesion.
Collapse
Affiliation(s)
- Fabiana Diaz‐Churion
- Division of Pulmonary, Allergy, and Sleep MedicineMayo ClinicJacksonvilleFloridaUSA
| | | | - David Abia‐Trujillo
- Division of Pulmonary, Allergy, and Sleep MedicineMayo ClinicJacksonvilleFloridaUSA
| | - Margaret M. Johnson
- Division of Pulmonary, Allergy, and Sleep MedicineMayo ClinicJacksonvilleFloridaUSA
| | - Andras Khoor
- Department of Laboratory Medicine and PathologyMayo ClinicJacksonvilleFloridaUSA
| | - Neal M. Patel
- Division of Pulmonary, Allergy, and Sleep MedicineMayo ClinicJacksonvilleFloridaUSA
| | - Janani Reisenauer
- Division of General Thoracic SurgeryMayo Clinic RochesterRochesterMinnesotaUSA
| | | |
Collapse
|
4
|
Johnson KA, Parkinson C, Johnson MM, Hamburger ML. Using telemedicine interventions during COVID-19 to expand care post COVID-19. Am J Manag Care 2023; 29:e31-e35. [PMID: 36716162 DOI: 10.37765/ajmc.2023.89311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Despite available technology and supportive evidence in the literature, the integration of telemedicine interventions in the US health care system has remained sluggish for decades. The COVID-19 pandemic catalyzed widespread utilization of virtual visits and remote monitoring in urgent, primary, and specialist care settings out of sheer necessity. Specifically, in the rheumatology subspecialty, a lack of available providers and a patient community hindered by mobility and access issues have underscored the value of telemedicine. For these reasons, a solutions-focused, multistakeholder virtual roundtable meeting convened by the Frances Hamburger Institute for Community Rheumatology (FHI) identified telemedicine as a critical area for intervention to improve the quality and cost-effectiveness of patient-centered care. Building upon stakeholder experience and published findings, the Patient-Centered Rheumatology Collaborative identified the continued deregulation of policy barriers and the facilitation of sustainable coverage and reimbursement as critical steps toward establishing a robust infrastructure for telemedicine post pandemic. FHI roundtable attendees acknowledged several remaining telemedicine access barriers concerning traditionally underserved patient populations that will need to be addressed to realize the full potential of telemedicine. These recommendations are in concordance with those of other recent consensus groups, and they legitimize the formation of collaborative frameworks among payers, providers, and other key stakeholders to advance care in rheumatology.
Collapse
Affiliation(s)
- Kjel A Johnson
- CVS Health, 695 George Washington Hwy, Lincoln, RI 02865.
| | | | | | | |
Collapse
|
5
|
Yu Lee-Mateus A, Reisenauer J, Garcia-Saucedo JC, Abia-Trujillo D, Buckarma EH, Edell ES, Grage RA, Bowman AW, Labarca G, Johnson MM, Patel NM, Fernandez-Bussy S. Robotic-assisted bronchoscopy versus CT-guided transthoracic biopsy for diagnosis of pulmonary nodules. Respirology 2023; 28:66-73. [PMID: 36104312 DOI: 10.1111/resp.14368] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 08/18/2022] [Indexed: 02/03/2023]
Abstract
BACKGROUND AND OBJECTIVE Currently, computed tomography-guided transthoracic biopsy (CTTB) is the most accurate diagnostic approach for pulmonary nodules suspected of malignancy. Traditional bronchoscopy has shown suboptimal diagnostic sensitivity, but the emergence of robotic-assisted bronchoscopy (RAB) has the potential to improve diagnostic accuracy, maximize diagnostic yield and complete mediastinal and hilar staging in a single procedure. We aim to assess the efficacy and diagnostic performance of RAB compared to CTTB for diagnosing pulmonary nodules suspected of lung cancer. METHODS A multicenter retrospective review of consecutive patients who underwent RAB and CTTB for evaluating pulmonary nodules from January 2019 to March 2021 at Mayo Clinic Florida and Mayo Clinic Rochester, United States. Clinical and demographic information, nodule characteristics, outcomes and complications were compared between RAB and CTTB. RESULTS A total of 225 patients were included: 113 in the RAB group and 112 in the CTTB group. Overall diagnostic yield was 87.6% for RAB and 88.4% for CTTB. For malignant disease, RAB had a sensitivity of 82.1% and a specificity of 100%, CTTB had a sensitivity of 88.5% and a specificity of 100%. Complication rate was significantly higher for CTTB compared to RAB (17% vs. 4.4%; p = 0.002). CONCLUSION RAB, when available, can be as accurate as CTTB for sampling pulmonary nodules with similar or reduced complications and should be considered as a means for nodule biopsy, particularly when mediastinal staging is also clinically warranted.
Collapse
Affiliation(s)
| | - Janani Reisenauer
- Department of Pulmonary Medicine and Thoracic Surgery, Mayo Clinic, Rochester, Minnesota, USA
| | - Juan C Garcia-Saucedo
- Internal Medicine Resident, Department of Internal Medicine, Morristown Medical Center, Morristown, New Jersey, USA
| | - David Abia-Trujillo
- Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | | | - Eric S Edell
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Rolf A Grage
- Department of Radiology, Mayo Clinic, Jacksonville, Florida, USA
| | - Andrew W Bowman
- Department of Radiology, Mayo Clinic, Jacksonville, Florida, USA
| | - Gonzalo Labarca
- Division of Sleep and Circadian Disorders, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Margaret M Johnson
- Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | - Neal M Patel
- Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | | |
Collapse
|
6
|
Hazelett BN, Paton A, Majid A, Johnson MM, Patel NM, Abia-Trujillo D, Lee-Mateus AY, Kornafeld A, Fernandez-Bussy S. Coordination of Care for Expiratory Central Airway Collapse: A Structured Process for a Multifaceted Disease. Chest 2023; 163:185-191. [PMID: 36243063 DOI: 10.1016/j.chest.2022.09.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Revised: 09/29/2022] [Accepted: 09/30/2022] [Indexed: 11/07/2022] Open
Abstract
Common respiratory symptoms, including dyspnea, cough, sputum production, and recurrent infections, frequently remain without a clear cause and may be the result of expiratory central airway collapse (ECAC). Establishing the diagnosis and appropriate treatment plan for patients with ECAC is challenging and benefits from a multidisciplinary approach. A coordinator role is crucial in this process to ensure optimal patient-centered outcomes. We describe the coordination of care in the process of diagnosing and treating ECAC. The coordinator leads the organization of the multiple services involved in the care of patients with ECAC, including pulmonary medicine, interventional pulmonology, radiology, and thoracic surgery, as well as hospital inpatient staff. From initial screening to evaluation and management with airway stents and corrective treatment with tracheobronchoplasty, the ECAC coordinator oversees the entire process of care for patients with ECAC.
Collapse
Affiliation(s)
- Britney N Hazelett
- Division of Pulmonary, Allergy, Sleep Medicine and Respiratory Services.
| | - Alichia Paton
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Adnan Majid
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | | | - Neal M Patel
- Division of Pulmonary, Allergy, Sleep Medicine and Respiratory Services
| | | | | | - Anna Kornafeld
- Division of Internal Medicine, Mayo Clinic Florida, Jacksonville, FL
| | | |
Collapse
|
7
|
Ritchie CA, Johnson MM, Stowell JT, Idrees H, Toskich B, Paz-Fumagalli R, Montazeri S, Fortich S, Franco-Mesa C, Gloviczki P, Bjarnason H, Rivera C, Shaikh M, Moreno-Franco P, Sanghavi D, Marquez CP, McBane RD, Park MS, O’Horo JC, Meschia JF, Erben Y. Resolution of Acute Pulmonary Embolism using anticoagulation therapy alone in Coronavirus Disease 2019. J Vasc Surg Venous Lymphat Disord 2022; 10:578-584.e2. [PMID: 35085829 PMCID: PMC8786402 DOI: 10.1016/j.jvsv.2021.12.086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 12/10/2021] [Indexed: 12/15/2022]
Abstract
Objective Methods Results Conclusions
Collapse
|
8
|
Fernandez-Bussy S, Kornafeld A, Labarca G, Abia-Trujillo D, Patel NM, Johnson MM, Reisenauer JS, Herth FJ. Risk of complications rise with coronary artery disease and diabetes mellitus after endobronchial valve placement in severe heterogeneous emphysema. Clin Respir J 2021; 15:1194-1200. [PMID: 34302313 DOI: 10.1111/crj.13426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Revised: 07/03/2021] [Accepted: 07/15/2021] [Indexed: 11/27/2022]
Abstract
BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) commonly have comorbidities which may impact both symptoms and prognosis. Endoscopic lung volume reduction (ELVR) with endobronchial valves (EBV) is an innovative, effective and safe treatment for patients with severe emphysema who remain symptomatic despite optimal medical therapy. OBJECTIVES To evaluate medical comorbidities associated with increased risk of complications after EBV procedure. METHOD This was a retrospective cohort review of patients with severe, heterogeneous emphysema who underwent Zephyr® EBV installation for ELVR. Demographics, baseline comorbidities, dyspnea scores, data regarding procedure, pulmonary function test, minimal clinically important difference and post-EBV complications were recorded. RESULTS Of a total 82 participants, 24 were identified as having a post procedure complication. There was a significant difference in the incidence of type 2 diabetes mellitus (T2DM) at baseline (25%) in complication group compared with non-complication group (5.1%) (p value = 0.01). There was also a significant difference between baseline coronary artery disease (CAD) in those with (58.3%) or without (29.3%) complication (p = 0.01). Multivariate analysis of other covariables, identified associations of both CAD and T2DM with a heightened risk of complication (adjusted OR 4.19 CI: 1.23-14.2, p value = 0.02 and adjusted OR of 6.1 CI: 1.3-26.1, p value = 0.02 respectively). CONCLUSIONS Our study found that patients with severe, heterogeneous emphysema who undergo ELVR utilizing Zephyr® EBV and suffer complications during post-procedure period are more likely to have CAD or T2DM as baseline comorbidity. These data suggest that baseline CAD and T2DM might be predictive of increased risk of complications following ELVR with EBV.
Collapse
Affiliation(s)
| | - Anna Kornafeld
- Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | - Gonzalo Labarca
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, University of Concepcion, Concepcion, Chile
| | | | - Neal M Patel
- Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | | | | | - Felix J Herth
- Department of Pulmonology and Respiratory Care Medicine, Thoraxklinik at the University of Heidelberg, Heidelberg, Germany.,Translational Lung Research Center Heidelberg (TLRCH), Heidelberg, Germany
| |
Collapse
|
9
|
Munner MS, Ritchie CA, Elkhidir IH, Mohammadat DT, Ahmed HJ, Altayeb KA, Yassin RZ, Hassan RM, Hamad SA, Nimir M, Hamid OS, Johnson MM, Narula T, Erben Y, Tawk RG, Miller DA, Gupta V, Devcic Z, Freeman WD, Toskich BB. Incidence of acute pulmonary embolism among patients hospitalized with COVID-19: a systematic review and meta-analysis. F1000Res 2021. [DOI: 10.12688/f1000research.27425.2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a global pandemic, which is associated with venous thromboembolism and pulmonary embolism (PE). This study aimed to estimate the pooled incidence of PE among patients hospitalized with COVID-19 within the published literature. Methods: This systematic review and meta-analysis was performed according to PRISMA guidelines. An electronic search using MEDLINE /PubMed, ScienceDirect, Cochrane, and OpenGray databases was conducted May 19th, 2020. Eligible studies included sufficient data to calculate the incidence of PE diagnosed during hospitalization in patients with COVID-19. Case reports were excluded. Quality was assessed using the Newcastle-Ottawa scale (observational cohort and case-control), AXIS tool (cross-sectional), and quality assessment tool (case series). Demographics and PE incidence data were extracted from the included studies and analyzed with R language. The pooled incidence of PE in patients hospitalized with COVID-19 was calculated. Results: The database search identified 128 records. Ten observational studies were eligible and were included in the meta-analysis with a total of 1722 patients (mean age= 63.36). .The incidence of PE was noted to be higher in males. The D-dimer levels were specified between PE group and non-PE group in only three studies, while the remaining either reported it improperly or had missing data.The pooled PE incidence in patients hospitalized with COVID-19 was 17% (95% CI: 0.1-0.26). There was a high degree of study heterogeneity (I2 = 94%, p<0.01). Conclusion: The pooled PE incidence in patients hospitalized with COVID-19 is 17%. This increased incidence is greater than that previously reported in the general population of non-COVID-19. Attention and further investigation of this risk is warranted.
Collapse
|
10
|
Willey D, Garcia-Saucedo J, Stancampiano F, Heckman MG, Klopman Z, Koralewski A, Crawford M, Johnson MM. Safety and Diagnostic Yield of Transthoracic Needle Aspiration of the Lung in Elderly Patients. Lung 2021; 199:171-176. [PMID: 33709231 DOI: 10.1007/s00408-021-00429-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Accepted: 02/17/2021] [Indexed: 12/19/2022]
Abstract
BACKGROUND Pulmonary nodules in elderly patients are commonly encountered in clinical practice. Tissue sampling with image guided transthoracic needle aspiration is often performed but may be complicated by pneumothorax or bleeding. To understand the outcomes of transthoracic needle aspiration in the elderly, we retrospectively reviewed outcomes of patients age 75 or greater in a single tertiary center. METHODS Four-hundred eleven patients age 75 or greater with a pulmonary nodule identified on computed tomography who underwent needle aspiration of the lung were studied. Diagnostic yield and procedural complications were assessed for each patient and subgroups analysis of those age 85 or greater was performed. RESULTS Malignancy was confirmed in 70% of subjects and a benign diagnosis identified in 9%. Of the 411 patents, 203 (49.4%) experienced a complication; 150 patients (36.5%) developed a pneumothorax and 79 (19.2%) had bleeding. No patient required transfusion, experienced persistent air leak or massive hemoptysis, air embolism or death. Post procedural hospitalization was required in 36 patients (8.8%) with a median hospital stay of 2 days. No factors were identified to be associated with occurrence of a complication (all p ≥ 0.16) and complications were not increased in those 85 or greater. CONCLUSION Our results suggest that in an elderly population, image guided needle aspiration of a pulmonary nodule provides diagnostic findings in most patients. Procedural complications following are not uncommon but the severity and long-term impact are limited. The occurrence of complications is similar in those age 75-84 and age 85 and older.
Collapse
Affiliation(s)
- Drew Willey
- Division of Community Internal Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA
| | - Juan Garcia-Saucedo
- Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL, 32224, USA
| | - Fernando Stancampiano
- Division of Community Internal Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA
| | - Michael G Heckman
- Department of Biomedical Statistics and Informatics, Mayo Clinic Florida, Jacksonville, Florida, USA
| | - Zachary Klopman
- Clinical Research Internship Study Program participant, Mayo Clinic, Jacksonville, Florida, USA
| | - Andrea Koralewski
- Clinical Research Internship Study Program participant, Mayo Clinic, Jacksonville, Florida, USA
| | - Matthew Crawford
- Clinical Research Internship Study Program participant, Mayo Clinic, Jacksonville, Florida, USA
| | - Margaret M Johnson
- Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
| |
Collapse
|
11
|
Johnson MM, Karnatovskaia LV, Niven AS. In Reply-The Role of Stress Perception for Clinical Implications of Stress. Mayo Clin Proc 2021; 96:509-510. [PMID: 33549275 DOI: 10.1016/j.mayocp.2020.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Accepted: 12/11/2020] [Indexed: 11/27/2022]
Affiliation(s)
| | | | - Alexander S Niven
- Mayo Clinic, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Rochester, MN
| |
Collapse
|
12
|
Choate R, Aksamit TR, Mannino D, Addrizzo-Harris D, Barker A, Basavaraj A, Daley CL, Daniels MLA, Eden E, DiMango A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, McShane PJ, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Winthrop KL, Stone G. Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study. Respir Med 2021; 177:106285. [PMID: 33401148 DOI: 10.1016/j.rmed.2020.106285] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Revised: 10/05/2020] [Accepted: 12/16/2020] [Indexed: 01/19/2023]
Abstract
RATIONALE Non-cystic fibrosis bronchiectasis (NCFB) is characterized by dilated bronchi, poor mucus clearance and susceptibility to bacterial infection. Pseudomonas aeruginosa (PA) is one of the most frequently isolated pathogens in patients with NCFB. The purpose of this study was to evaluate the association between presence of PA and disease severity in patients within the US Bronchiectasis and Nontuberculous mycobacteria (NTM) Research Registry (BRR). METHODS Baseline US BRR data from adult patients with NCFB collected between 2008 and 2018 was used for this study. The presence of PA was defined as one or more positive PA cultures within two years prior to enrollment. Modified Bronchiectasis Severity Index (m-BSI) and modified FACED (m-FACED) were computed to evaluate severity of bronchiectasis. Unadjusted and multivariable multinomial regression models were used to assess the association between presence of PA and severity of bronchiectasis. RESULTS Average age of the study participants (n = 1831) was 63.7 years (SD = 14.1), 91.5% white, and 78.8% female. Presence of PA was identified in 25.4% of the patients. Patients with presence of PA had significantly lower mean pre-bronchodilator FEV1% predicted compared to those without PA (62.8% vs. 73.7%, p < .0001). In multivariate analyses, patients with presence of PA had significantly greater odds for having high (ORadj = 6.15 (95%CI:3.98-9.50) and intermediate (ORadj = 2.06 (95%CI:1.37-3.09) severity vs. low severity on m-BSI. CONCLUSION The presence of PA is common in patients with NCFB within the Bronchiectasis and NTM Research Registry. Severity of bronchiectasis is significantly greater in patients with PA which emphasizes high burden of the disease.
Collapse
Affiliation(s)
- Radmila Choate
- University of Kentucky, College of Public Health, Lexington, KY, USA; Research, COPD Foundation, USA.
| | - Timothy R Aksamit
- Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
| | - David Mannino
- University of Kentucky, College of Medicine, Lexington, KY, USA
| | | | - Alan Barker
- Department of Pulmonology, OHSU School of Medicine, Portland, OR, USA
| | | | - Charles L Daley
- Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA
| | | | - Edward Eden
- Icahn School of Medicine, Mt. Sinai West and Mt. Sinai St Luke's Hospitals, Mt. Sinai, NY, USA
| | - Angela DiMango
- Columbia College of Physicians and Surgeons, Center for Chest Disease, New York, NY, USA
| | - Kevin Fennelly
- National Heart Lung and Blood Institute, NIH, Bethesda, MD, USA
| | | | | | | | - Pamela J McShane
- University of Texas Health Science Center at Tyler, Tyler, TX, USA
| | - Mark L Metersky
- Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, Farmington, CT, USA
| | - Peadar G Noone
- University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | | | | | | | - Andreas Schmid
- University of Kansas Medical Center, Kansas City, KS, USA
| | - Byron Thomashow
- Columbia College of Physicians and Surgeons, Center for Chest Disease, New York, NY, USA
| | - Gregory Tino
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Kevin L Winthrop
- Department of Pulmonology, OHSU School of Medicine, Portland, OR, USA; Department of Infectious Disease, OHSU School of Medicine, Portland, OR, USA
| | | |
Collapse
|
13
|
Abia-Trujillo D, Johnson MM, Patel NM, Hazelett B, Edell ES, Kern RM, Midthun D, Reisenauer J, Nelson D, Mullon JJ, Sakata KK, Swanson K, Fernandez-Bussy S. Bronchoscopic Lung Volume Reduction: A New Hope for Patients With Severe Emphysema and Air Trapping. Mayo Clin Proc 2021; 96:464-472. [PMID: 32829903 DOI: 10.1016/j.mayocp.2020.03.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 03/25/2020] [Accepted: 03/31/2020] [Indexed: 10/23/2022]
Abstract
Chronic obstructive pulmonary disease (COPD) is common and has significant morbidity and mortality as the fourth leading cause of death in the United States. In many patients, particularly those with emphysema, COPD is characterized by markedly increased residual volume contributing to exertional dyspnea. Current therapies have limited efficacy. Surgical resection of diseased areas of the lung to reduce residual volume was effective in identified subgroups but also had significant mortality in and suboptimal cost effectiveness. Lung-volume reduction, using bronchoscopic techniques, has shown substantial benefits in a broader patient population with less morbidity and mortality. This review is meant to spread the awareness about bronchoscopic lung-volume reduction and to promote its consideration and early referral for patients with advanced COPD and emphysema frequently encountered by both primary care physicians and specialists. A search was conducted on PubMed (MEDLINE), EMbase, and Cochrane library for original studies, using the following keywords: "lung-volume reduction." "endobronchial valves," "intrabronchial valves," "bronchoscopic lung-volume reduction," and "endoscopic lung-volume reduction." We included reports from systematic reviews, narrative reviews, clinical trials, and observational studies. Two reviewers evaluated potential references. A total of 27 references were included in our review. Included studies report experience in the diagnosis and bronchoscopic treatment for emphysema; case reports and non-English or non-Spanish studies were excluded.
Collapse
Affiliation(s)
- David Abia-Trujillo
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic Florida, Jacksonville, FL
| | - Margaret M Johnson
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic Florida, Jacksonville, FL
| | - Neal M Patel
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic Florida, Jacksonville, FL
| | - Britney Hazelett
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic Florida, Jacksonville, FL
| | - Eric S Edell
- Division of Pulmonary Medicine, Mayo Clinic, Rochester, MN
| | - Ryan M Kern
- Division of Pulmonary Medicine, Mayo Clinic, Rochester, MN
| | - David Midthun
- Division of Pulmonary Medicine, Mayo Clinic, Rochester, MN
| | | | - Darlene Nelson
- Division of Pulmonary Medicine, Mayo Clinic, Rochester, MN
| | - John J Mullon
- Division of Pulmonary Medicine, Mayo Clinic, Rochester, MN
| | | | - Karen Swanson
- Division of Pulmonary Medicine, Mayo Clinic, Phoenix, AZ
| | | |
Collapse
|
14
|
Hazelett BN, Paton A, Majid A, Schreefer K, Folch E, Johnson MM, Patel NM, Abia-Trujillo D, Fernandez-Bussy S. Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction With Endobronchial Valves. Chest 2020; 159:2090-2098. [PMID: 33338444 DOI: 10.1016/j.chest.2020.11.041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Revised: 11/06/2020] [Accepted: 11/30/2020] [Indexed: 11/25/2022] Open
Abstract
COPD may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight, which can be achieved by a BLVR nurse coordinator (NC). By identifying and developing screening practices, coordinating multidisciplinary diagnostic evaluation, and establishing safe efficient patient flow throughout the entire care process, a BLVR NC can optimize patient care, safety, experience, efficiency, and overall outcomes. This article details the role of our NC to facilitate extrapolation to other institutions.
Collapse
Affiliation(s)
- Britney N Hazelett
- Division of Pulmonary, Allergy, Sleep Medicine, and Respiratory Services, Mayo Clinic in Florida, Jacksonville, FL.
| | - Alichia Paton
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Adnan Majid
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Kimberly Schreefer
- Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital-Harvard Medical School, Boston, MA
| | - Erik Folch
- Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital-Harvard Medical School, Boston, MA
| | - Margaret M Johnson
- Division of Pulmonary, Allergy, Sleep Medicine, and Respiratory Services, Mayo Clinic in Florida, Jacksonville, FL
| | - Neal M Patel
- Division of Pulmonary, Allergy, Sleep Medicine, and Respiratory Services, Mayo Clinic in Florida, Jacksonville, FL
| | - David Abia-Trujillo
- Division of Pulmonary, Allergy, Sleep Medicine, and Respiratory Services, Mayo Clinic in Florida, Jacksonville, FL
| | - Sebastian Fernandez-Bussy
- Division of Pulmonary, Allergy, Sleep Medicine, and Respiratory Services, Mayo Clinic in Florida, Jacksonville, FL
| |
Collapse
|
15
|
Abia-Trujillo D, Majid A, Johnson MM, Mira-Avendano I, Patel NM, Makey IA, Thomas M, Kornafeld A, Hazelett BN, Fernandez-Bussy S. Central Airway Collapse, an Underappreciated Cause of Respiratory Morbidity. Mayo Clin Proc 2020; 95:2747-2754. [PMID: 32829904 DOI: 10.1016/j.mayocp.2020.03.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 01/17/2020] [Accepted: 03/06/2020] [Indexed: 10/23/2022]
Abstract
Dyspnea, cough, sputum production, and recurrent respiratory infections are frequently encountered clinical concerns leading patients to seek medical care. It is not unusual for a well-defined etiology to remain elusive or for the therapeutics of a presumed etiology to be incompletely effective. Either scenario should prompt consideration of central airway pathology as a contributor to clinical manifestations. Over the past decade, recognition of dynamic central airway collapse during respiration associated with multiple respiratory symptoms has become more commonly appreciated. Expiratory central airway collapse may represent the answer to this diagnostic void. Expiratory central airway collapse is an underdiagnosed disorder that can coexist with and mimic asthma, chronic obstructive pulmonary disease, and bronchiectasis. Awareness of expiratory central airway collapse and its spectrum of symptoms is paramount to its recognition. This review includes clear definitions, diagnostics, and therapeutics for this challenging condition. We performed a narrative review through the PubMed (MEDLINE) database using the following MeSH terms: airway collapse, tracheobronchomalacia, tracheomalacia, and bronchomalacia. We include reports from systematic reviews, narrative reviews, clinical trials, and observational studies from 2005 to 2020. Two reviewers evaluated potential references. No systematic reviews were found. A total of 28 references were included into our review. Included studies report experience in the diagnosis and/or treatment of dynamic central airway collapse; case reports and non-English or non-Spanish studies were excluded. We describe the current diagnostic dilemma, highlighting the role of dynamic bronchoscopy and tracheobronchial stent trial; outline the complex therapeutic options (eg, tracheobronchoplasty); and present future directions and challenges.
Collapse
Affiliation(s)
- David Abia-Trujillo
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL
| | - Adnan Majid
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Margaret M Johnson
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL
| | - Isabel Mira-Avendano
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL
| | - Neal M Patel
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL
| | - Ian A Makey
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL
| | - Mathew Thomas
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL
| | - Anna Kornafeld
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL
| | - Britney N Hazelett
- Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL
| | | |
Collapse
|
16
|
Karnatovskaia LV, Johnson MM, Varga K, Highfield JA, Wolfrom BD, Philbrick KL, Ely EW, Jackson JC, Gajic O, Ahmad SR, Niven AS. Stress and Fear: Clinical Implications for Providers and Patients (in the Time of COVID-19 and Beyond). Mayo Clin Proc 2020; 95:2487-2498. [PMID: 33153636 PMCID: PMC7606075 DOI: 10.1016/j.mayocp.2020.08.028] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 08/13/2020] [Accepted: 08/25/2020] [Indexed: 12/27/2022]
Abstract
In light of the coronavirus disease 2019 pandemic, we explore the role of stress, fear, and the impact of positive and negative emotions on health and disease. We then introduce strategies to help mitigate stress within the health care team, and provide a rationale for their efficacy. Additionally, we identify strategies to optimize patient care and explain their heightened importance in today's environment.
Collapse
Affiliation(s)
| | | | - Katalin Varga
- Affective Psychology Department, Eötvös Loránd University, Budapest, Hungary
| | - Julie A Highfield
- Department of Clinical Psychology in Critical Care, University Hospital Wales, Cardiff, UK
| | - Brent D Wolfrom
- Department of Family Medicine, Queen's University, Kingston, Canada
| | | | - E Wesley Ely
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Vanderbilt University Medical Center, Nashville, TN; Geriatric Research, Education and Clinical Center (GRECC), Tennessee Valley Veterans Affairs Healthcare System, Nashville, TN
| | - James C Jackson
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | | | | | | |
Collapse
|
17
|
Despotes KA, Choate R, Addrizzo-Harris D, Aksamit TR, Barker A, Basavaraj A, Daley CL, Eden E, DiMango A, Fennelly K, Philley J, Johnson MM, McShane PJ, Metersky ML, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Winthrop KL, Knowles MR, Daniels MLA, Noone PG. Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. Chronic Obstr Pulm Dis 2020; 7:390-403. [PMID: 33108111 PMCID: PMC7883909 DOI: 10.15326/jcopdf.7.4.2020.0178] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 06/30/2020] [Indexed: 11/21/2022]
Abstract
BACKGROUND Increasing numbers of patients are being diagnosed with bronchiectasis, yet much remains to be elucidated about this heterogeneous patient population. We sought to determine the relationship between nutrition and health outcomes in non-cystic fibrosis (non-CF) bronchiectasis, using data from the U.S. Bronchiectasis Nontuberculous Mycobacterial Research Registry (U.S. BRR). METHODS This was a retrospective, observational, longitudinal study using 5-year follow-up data from the BRR. Bronchiectasis was confirmed on computed tomography (CT). We stratified patients into nutrition categories using body mass index (BMI), and correlated BMI to markers of disease severity. RESULTS Overall, n = 496 patients (mean age 64.6- ± 13 years; 83.3% female) were included. At baseline 12.3% (n = 61) were underweight (BMI < 18.5kg/m2), 63.9% (n = 317) had normal weight (BMI ≥ 18.5kg/m2 and <25.0kg/m2), 17.3% (n = 86) were overweight (BMI ≥ 25.0kg/m2 and < 30.0kg/m2), and 6.5% (n= 32) were obese (BMI ≥ 30kg/m2). Men were overrepresented in the overweight and obese groups (25.6% and 43.8% respectively, p < 0.0001). Underweight patients had lower lung function (forced expiratory volume in 1 second [FEV1] % predicted) than the other weight groups (64.5 ± 22, versus 73.5 ± 21, 68.5 ± 20, and 76.5 ± 21 in normal, overweight, and obese groups respectively, p = 0.02). No significant differences were noted between BMI groups for other markers of disease severity at baseline, including exacerbation frequency or hospitalization rates. No significant differences were noted in BMI distribution between patients with and without Pseudomonas, non-tuberculous mycobacteria, or by cause of bronchiectasis. The majority of patients demonstrated stable BMI over 5 years. CONCLUSIONS Although underweight patients with bronchiectasis have lower lung function, lower BMI does not appear to relate to other markers of disease severity in this patient population.
Collapse
Affiliation(s)
| | - Radmila Choate
- Research, COPD Foundation, Washington, DC
- College of Public Health, University of Kentucky, Lexington
| | | | - Timothy R Aksamit
- Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota
| | - Alan Barker
- Department of Pulmonary and Critical Care, School of Medicine, Oregon Health and Science University, Portland
| | | | - Charles L Daley
- Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado
| | - Edward Eden
- Icahn School of Medicine, Mt. Sinai West and Mt. Sinai St Luke's Hospitals, Mt. Sinai, New York
| | - Angela DiMango
- Center for Chest Disease, Columbia College of Physicians and Surgeons, New York, New York
| | - Kevin Fennelly
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | | | | | - Pamela J McShane
- Department of Medicine, University of Chicago, Chicago, Illinois
| | - Mark L Metersky
- Division of Pulmonary and Critical Care Medicine, School of Medicine, University of Connecticut, Farmington
| | | | - Kenneth N Olivier
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | | | | | - Byron Thomashow
- Center for Chest Disease, Columbia College of Physicians and Surgeons, New York, New York
| | - Gregory Tino
- Perelman School of Medicine, University of Pennsylvania, Philadelphia
| | - Kevin L Winthrop
- Department of Pulmonary and Critical Care, School of Medicine, Oregon Health and Science University, Portland
- Department of Infectious Disease, School of Medicine, Oregon Health and Science University School of Medicine, Portland
| | | | | | - Peadar G Noone
- Department of Medicine, University of North Carolina at Chapel Hill
| |
Collapse
|
18
|
Basavaraj A, Choate R, Addrizzo-Harris D, Aksamit TR, Barker A, Daley CL, Anne Daniels ML, Eden E, DiMango A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Winthrop KL. Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry. Chest 2020; 158:1376-1384. [PMID: 32622820 DOI: 10.1016/j.chest.2020.06.050] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Revised: 06/02/2020] [Accepted: 06/04/2020] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND In patients with bronchiectasis, airway clearance techniques (ACTs) are important management strategies. RESEARCH QUESTION What are the differences in patients with bronchiectasis and a productive cough who used ACTs and those who did not? What was the assessment of bronchiectasis exacerbation frequency and change in pulmonary function at 1-year follow up? STUDY DESIGN AND METHODS Adult patients with bronchiectasis and a productive cough in the United States Bronchiectasis and NTM Research Registry were included in the analyses. ACTs included the use of instrumental devices and manual techniques. Stratified analyses of demographic and clinical characteristics were performed by use of ACTs at baseline and follow up. The association between ACT use and clinical outcomes was assessed with the use of unadjusted and adjusted multinomial logistic regression models. RESULTS Of the overall study population (n = 905), 59% used ACTs at baseline. A greater proportion of patients who used ACTs at baseline and follow up continuously had Pseudomonas aeruginosa (47% vs 36%; P = .021) and experienced an exacerbation (81% vs 59%; P < .0001) or hospitalization for pulmonary illness (32% vs 22%; P = .001) in the prior two years, compared with those patients who did not use ACTs. Fifty-eight percent of patients who used ACTs at baseline did not use ACTs at 1-year follow up. There was no significant change in pulmonary function for those who used ACTs at follow up, compared with baseline. Patients who used ACTs at baseline and follow up had greater odds for experiencing exacerbations at follow up compared with those patients who did not use ACTs. INTERPRETATION In patients with bronchiectasis and a productive cough, ACTs are used more often if the patients have experienced a prior exacerbation, hospitalization for pulmonary illness, or had P aeruginosa. There is a significant reduction in the use of ACTs at 1-year follow up. The odds of the development of a bronchiectasis exacerbation are higher in those patients who use ACTs continuously, which suggests more frequent use in an ill bronchiectasis population.
Collapse
Affiliation(s)
| | - Radmila Choate
- Research, the COPD Foundation, Miami, FL; College of Public Health, University of Kentucky, Lexington, KY
| | | | - Timothy R Aksamit
- Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, MN
| | - Alan Barker
- Department of Pulmonology, OHSU School of Medicine, Portland, OR
| | - Charles L Daley
- Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO
| | | | - Edward Eden
- Icahn School of Medicine, Mt Sinai West and Mt Sinai St Luke's Hospitals, Mt Sinai, NY
| | - Angela DiMango
- Center for Chest Disease, Columbia College of Physicians and Surgeons, New York, NY
| | - Kevin Fennelly
- National Heart Lung and Blood Institute, NIH, Bethesda, MD
| | | | | | | | - Mark L Metersky
- Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, Farmington, CT
| | - Peadar G Noone
- University of North Carolina at Chapel Hill, Chapel Hill, NC
| | | | | | | | - Andreas Schmid
- University of Miami Miller School of Medicine, Miami, FL
| | - Byron Thomashow
- Center for Chest Disease, Columbia College of Physicians and Surgeons, New York, NY
| | - Gregory Tino
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Kevin L Winthrop
- Department of Pulmonology, OHSU School of Medicine, Portland, OR; Department of Infectious Disease, OHSU School of Medicine, Portland, OR
| |
Collapse
|
19
|
Karnatovskaia LV, Schulte PJ, Philbrick KL, Johnson MM, Anderson BK, Gajic O, Clark MM. Psychocognitive sequelae of critical illness and correlation with 3 months follow up. J Crit Care 2019; 52:166-171. [PMID: 31078997 DOI: 10.1016/j.jcrc.2019.04.028] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 03/22/2019] [Accepted: 04/27/2019] [Indexed: 01/08/2023]
Abstract
PURPOSE Over a third of critical illness survivors manifest significant psychocognitive impairments following discharge from the intensive care unit (ICU). It is not known which patient populations are at highest risk or if assessment at ICU discharge can guide outpatient treatment prioritization. MATERIALS AND METHODS Prospective single center study in an academic medical center encompassing six types of ICUs assessed prevalence of psychocognitive morbidity based on ICU type and associations between initial and 3 month follow-up evaluation. Adult patients with >48 h ICU stays completed the Hospital Anxiety and Depression Scale (HADS), Impact of Events Scale-Revised (IES-R), and Montreal Cognitive Assessment-Blind (MoCA-blind). RESULTS Of 299 patients who underwent initial assessment, 174 (58%) completed follow-up. Length of stay, MoCA-Blind, HADS-A/D and IES-R scores were similar across ICUs. Most commonly observed impairment in-hospital was cognitive (58%) followed by anxiety (45%), acute stress (39%) and depression (37%). There were significant correlations between in-hospital and follow-up psychocognitive outcomes. CONCLUSIONS There was no significant difference in impairment by ICU type. Significant correlation between the initial assessment and follow-up scores suggests that early screening of high risk patients may identify those at greatest risk of sustained morbidity and facilitate timely intervention.
Collapse
Affiliation(s)
- Lioudmila V Karnatovskaia
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, United States of America.
| | - Phillip J Schulte
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States of America
| | - Kemuel L Philbrick
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America
| | - Margaret M Johnson
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville, FL, United States of America
| | - Brenda K Anderson
- Anesthesia Clinical Research Unit, Mayo Clinic, Rochester, MN, United States of America
| | - Ognjen Gajic
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, United States of America
| | - Matthew M Clark
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America
| |
Collapse
|
20
|
Eden E, Choate R, Barker A, Addrizzo-Harris D, Aksamit TR, Daley CL, Daniels MLA, DiMango A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Turino GM, Winthrop KL. The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry. Chronic Obstr Pulm Dis 2019; 6:145-153. [PMID: 30974050 DOI: 10.15326/jcopdf.6.2.2018.0156] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Objective This study compares and contrasts the clinical features of non-cystic fibrosis bronchiectasis with 3 uncommon disorders known to be associated with bronchiectasis but with distinctly different underlying defined pathophysiologic derangements, namely severe alpha-1 antitrypsin deficiency (AATD), common variable immunodeficiency (CVI) and primary ciliary dyskinesia (PCD). Methods The Bronchiectasis Research Registry provides a central database for studying patients with non-cystic fibrosis bronchiectasis. This report consists of information from 13 U.S. sites pertaining to the 3 study diagnoses. Patients with AATD (SZ and ZZ phenotypes only), CVI (patients with IgG≤500), PCD (history of physician diagnosed Kartagener's syndrome or PCD), and patients with confirmed absence of the above 3 diagnoses (idiopathic control group) were included in the study. Descriptive statistics were computed for the main demographic and clinical characteristics of the sample stratified by group. Values between the groups were compared using Kruskal-Wallis test, and Chi-squared/ Fisher's exact tests respectively. The significance level was set at 0.05. Software SAS 9.4 was used to perform the statistical analyses. Results Of the 2170 participants in the database enrolled as of January 2017, 615 respondents had sufficient data and were included in the analyses. Patients with PCD (n=79, mean age 41.9 years [standard deviation (SD)=14.5]) were significantly younger than patients with AATD (n=58, mean age 66.9 [SD=10.7]), CVI (n=18, mean age 66.7 years [SD=10.5]) or the idiopathic group (n=460, mean age 64.2 [SD=15.9]), p<.0001. Compared to other groups, those with PCD had lower pulmonary function (forced expiratory volume in 1 second [FEV1] forced vital capacity [FVC] and FEV1/FVC ratio) (p<0.01), and a greater proportion of them reported having exacerbations and/or hospitalizations in the past 2 years (p<0.01). Overall, Pseudomonas aeruginosa and Staphylococcus aureus were the organisms most commonly isolated from sputum. Mycobacterial infection was most commonly reported in those with AATD. Conclusion This report from the U.S. Bronchiectasis Research Registry compares and contrasts differences in the clinical features of patients suffering from 3 rare conditions, with different underlying causes, to those without. The group with PCD had more symptoms, greater morbidity, lower lung function and more commonly were infected by Pseudomonas aeruginosa. A greater percentage of those with AATD reported mycobacterial lung involvement.
Collapse
Affiliation(s)
- Edward Eden
- Icahn School of Medicine Mt Sinai, New York, New York
| | - Radmila Choate
- University of Kentucky College of Public Health, Lexington
| | - Alan Barker
- Oregon Health Sciences University Hospital, Portland
| | | | - Timothy R Aksamit
- Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota
| | - Charles L Daley
- Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado
| | | | - Angela DiMango
- Columbia College of Physicians and Surgeons, Center for Chest Disease, New York, New York
| | - Kevin Fennelly
- National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | | | | | | | - Mark L Metersky
- Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, Farmington
| | | | | | - Kenneth N Olivier
- National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | | | - Andreas Schmid
- University of Miami Miller School of Medicine, Miami, Florida
| | - Byron Thomashow
- Columbia College of Physicians and Surgeons, Center for Chest Disease, New York, New York
| | - Gregory Tino
- University of Pennsylvania Perelman School of Medicine, Philadelphia
| | | | - Kevin L Winthrop
- Oregon Health Sciences University Hospital, Portland.,Department of Infectious Disease, Oregon Health and Science University School of Medicine, Portland
| |
Collapse
|
21
|
Lou Y, Dholaria B, Soyano A, Hodge D, Cochuyt J, Manochakian R, Ko SJ, Thomas M, Johnson MM, Patel NM, Miller RC, Adjei AA, Ailawadhi S. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med 2018; 7:4932-4942. [PMID: 30175515 PMCID: PMC6198232 DOI: 10.1002/cam4.1749] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 07/22/2018] [Accepted: 08/04/2018] [Indexed: 12/15/2022] Open
Abstract
Background Treatment of non‐small‐cell lung cancer (NSCLC) has been rapidly advancing over the last decade. Academic centers are considered equipped with better expertise. NSCLC outcome trends in novel therapeutic era and impact of initial treatment at academic centers have not been reported. Methods The National Cancer Database (NCDB) was used to identify NSCLC incident cases from 2004 to 2013. Overall survival (OS) was plotted by year of diagnosis and type of initial treatment center, accounting for several factors available in NCDB. Results A total of 1 150 722 NSCLC patients were included and separated by initial treatment center type (academic: 31.5%; nonacademic: 68.5%). Median follow‐up and OS for all patients were 11.8 months (range: 0‐133.6 months) and 13.1 months (95% CI: 13.08‐13.17), respectively. Median OS improved significantly for those diagnosed in 2010‐2013 (14.8 months [95% CI: 14.7‐14.9]) as compared to 2004‐2009 (12.4 months [95% CI: 12.3‐12.5]) (P < 0.001). Treatment at academic centers was associated with improved OS (multivariate HR for OS = 0.929 [95% CI: 0.92‐0.94], P < 0.0010). Four‐year OS for academic and nonacademic cohorts was 28.5%% and 22.1%, respectively (P < 0.001), and the difference was more pronounced in stage I to III NSCLC. Conclusion In this largest analysis, thus far, NSCLC survival has improved over time, and type of initial treatment center significantly influences survival. Identifying and removing barriers to obtaining initial treatment of NSCLC at academic medical centers could improve OS.
Collapse
Affiliation(s)
- Yanyan Lou
- Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida
| | | | - Aixa Soyano
- Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida
| | - David Hodge
- Department of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida
| | - Jordan Cochuyt
- Department of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida
| | - Rami Manochakian
- Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida
| | - Stephen J Ko
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida
| | - Mathew Thomas
- Department of Cardiovascular Thoracic Surgery, Mayo Clinic, Jacksonville, Florida
| | - Margaret M Johnson
- Division of Allergy and Pulmonary Medicine, Mayo Clinic, Jacksonville, Florida
| | - Neal M Patel
- Division of Allergy and Pulmonary Medicine, Mayo Clinic, Jacksonville, Florida
| | - Robert C Miller
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida
| | - Alex A Adjei
- Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota
| | | |
Collapse
|
22
|
Waddle MR, Ko S, Johnson MM, Lou Y, Miller RC, Harrell AC, Trifiletti DM. Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy. Transl Lung Cancer Res 2018; 7:S171-S175. [PMID: 29782566 DOI: 10.21037/tlcr.2018.03.21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Mark R Waddle
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA
| | - Stephen Ko
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA
| | | | - Yanyan Lou
- Department of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA
| | - Robert C Miller
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA
| | - Anna C Harrell
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA
| | | |
Collapse
|
23
|
Sacco KA, Chirila R, Libertin C, Hiroto B, Bhasin A, Johnson MM, Pongdee T, Burton MC. Utilization and timeliness of an inpatient penicillin allergy evaluation. Allergy Asthma Proc 2018; 39:245-251. [PMID: 29669670 DOI: 10.2500/aap.2018.39.4118] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND A history of penicillin allergy is associated with an increased risk of nosocomial infections because patients are exposed to non-beta lactam antibiotics. Ruling out inaccurate penicillin allergy during hospitalization decreases prescription of beta lactam antibiotics. However, the utilization of penicillin allergy testing and timeliness in relation to initiation of antibiotics is not known. OBJECTIVE Our aim was to describe the proportion and characteristics of patients who underwent inpatient penicillin allergy testing in a hospital without a guideline or infrastructure for inpatient penicillin allergy testing. METHODS We performed a retrospective chart review of patients admitted to our institution between January 1, 2008, and December 31, 2015, who underwent penicillin allergy testing. RESULTS Forty-nine patients were identified; 27 (55.1%) were women. The median age was 61.5 years (interquartile range [IQR], 48.5-71 years). The median Charlson-Comorbidity index score was 4 (IQR, 2-5.5). Of these patients, 42.86% (21) were admitted to the intensive care unit, 79.6% of allergy consults were requested by infectious disease physicians, and 87.8% of patients were receiving non-beta lactam antibiotics at the time of testing. The patients received a median of 5 days of antibiotics before testing (range, 0-16 days; IQR, 3-7 days). Antimicrobial therapy was changed in 78.0% of the patients (32), of whom 68.3% (21/32) was attributable to penicillin allergy testing. CONCLUSION Inpatient penicillin allergy testing is a critical component of antibiotic stewardship; however, an adequate infrastructure is essential for timely evaluation. Inpatient penicillin allergy evaluation requires a multidisciplinary approach focused on patient selection; risk stratification; and optimization of a timely, safe, and cost-effective approach to optimize patient outcomes.
Collapse
Affiliation(s)
- Keith A. Sacco
- From the Department of Medicine, Mayo Clinic, Jacksonville, Florida
| | - Razvan Chirila
- From the Department of Medicine, Mayo Clinic, Jacksonville, Florida
| | - Claudia Libertin
- Division of Infectious Disease, Mayo Clinic, Jacksonville, Florida
| | - Brett Hiroto
- From the Department of Medicine, Mayo Clinic, Jacksonville, Florida
| | - Arveen Bhasin
- Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, Florida
| | | | - Thanai Pongdee
- Division of Allergy and Immunology, Mayo Clinic, Rochester, Minnesota
| | - M. Caroline Burton
- Division of Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota
| |
Collapse
|
24
|
Ruffner MA, Aksamit TR, Thomashow B, Choate R, DiMango A, Turino GM, O'Donnell AE, Johnson MM, Olivier KN, Fennelly K, Daley CL, Winthrop KL, Metersky ML, Salathe MA, Knowles MR, Daniels MLA, Noone PG, Tino G, Griffith DE, Sullivan KE. Frequency of untreated hypogammaglobulinemia in bronchiectasis. Ann Allergy Asthma Immunol 2017; 119:83-85. [PMID: 28539185 DOI: 10.1016/j.anai.2017.04.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Revised: 04/24/2017] [Accepted: 04/25/2017] [Indexed: 01/16/2023]
Affiliation(s)
- Melanie A Ruffner
- Division of Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Timothy R Aksamit
- Division of Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota
| | - Byron Thomashow
- Division of Pulmonary Critical Care Medicine, Columbia University Medical Center, New York, New York
| | - Radmila Choate
- Preventive Medicine and Environmental Health, University of Kentucky, Louisville, Kentucky
| | - Angela DiMango
- Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, New York
| | - Gerard M Turino
- Pulmonary Medicine, Mount Sinai Hospital, New York, New York
| | - Anne E O'Donnell
- Division of Pulmonary, Critical Care, and Sleep Medicine, Georgetown University Medical Center, Washington, DC
| | - Margaret M Johnson
- Division of Allergy and Pulmonary Medicine, Mayo Clinic Florida, Jacksonville, Florida
| | - Kenneth N Olivier
- Pulmonary Clinical Medicine Section, National Heart, Lung, and Blood Institute, Bethesda, Maryland
| | - Kevin Fennelly
- Pulmonary Clinical Medicine Section, National Heart, Lung, and Blood Institute, Bethesda, Maryland
| | - Charles L Daley
- Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado
| | - Kevin L Winthrop
- Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon
| | - Mark L Metersky
- UCONN Center for Bronchiectasis Care, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Matthias A Salathe
- Medicine Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, Miami, Florida
| | - Michael R Knowles
- Marsico Lung Institute/Cystic Fibrosis Research Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - M Leigh Anne Daniels
- Pulmonary Medicine and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - Peadar G Noone
- Pulmonary Medicine and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - Gregory Tino
- Pulmonary Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - David E Griffith
- Pulmonary Infectious Disease Section, University of Texas Health Science Center, Tyler, Texas
| | - Kathleen E Sullivan
- Division of Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
| |
Collapse
|
25
|
|
26
|
Berger J, Dunn JD, Johnson MM, Karst KR, Shear WC. How drug life-cycle management patent strategies may impact formulary management. Am J Manag Care 2016; 22:S487-S495. [PMID: 28719222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Drug manufacturers may employ various life-cycle management patent strategies, which may impact managed care decision making regarding formulary planning and management strategies when single-source, branded oral pharmaceutical products move to generic status. Passage of the Hatch-Waxman Act enabled more rapid access to generic medications through the abbreviated new drug application process. Patent expirations of small-molecule medications and approvals of generic versions have led to substantial cost savings for health plans, government programs, insurers, pharmacy benefits managers, and their customers. However, considering that the cost of developing a single medication is estimated at $2.6 billion (2013 dollars), pharmaceutical patent protection enables companies to recoup investments, creating an incentive for innovation. Under current law, patent protection holds for 20 years from time of patent filing, although much of this time is spent in product development and regulatory review, leaving an effective remaining patent life of 7 to 10 years at the time of approval. To extend the product life cycle, drug manufacturers may develop variations of originator products and file for patents on isomers, metabolites, prodrugs, new drug formulations (eg, extended-release versions), and fixed-dose combinations. These additional patents and the complexities surrounding the timing of generic availability create challenges for managed care stakeholders attempting to gauge when generics may enter the market. An understanding of pharmaceutical patents and how intellectual property protection may be extended would benefit managed care stakeholders and help inform decisions regarding benefit management.
Collapse
|
27
|
Bansal V, Mangi MA, Johnson MM, Festic E. Inhaled corticosteroids and incident pneumonia in patients with asthma: Systematic review and meta-analysis. Acta Med Acad 2016; 44:135-58. [PMID: 26702909 DOI: 10.5644/ama2006-124.141] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Accepted: 11/04/2015] [Indexed: 11/09/2022] Open
Abstract
OBJECTIVES To systematically review all available studies on inhaled corticosteroid use and incident pneumonia in asthma patients. METHODS We performed a literature search from January 1, 1993, through August 15, 2015, using PubMed, Medline, CENTRAL, EMBASE, Scopus, ISI, Regulatory Documents, Web of Science and manufacturers' web clinical trial registries with multiple search terms. We included studies that compared the risk of incident pneumonia among patients utilizing and not utilizing inhaled corticosteroids. We then summarized risk estimates into two random-effect meta-analyses; one including randomized controlled trials and another one including observational studies. RESULTS Fourteen studies were estimable; ten randomized controlled trials included 19,098 participants and four observational studies included 44,016 participants. There was no heterogeneity in randomized trials and summed risk ratio demonstrated the use of inhaled corticosteroids was protective of pneumonia; risk ratio 0.74, 95% CI 0.57 to 0.95, p=0.02. On the contrary, observational studies showed summed odds ratio of 1.97; 95% CI 1.87 to 2.07, p<0.0001, I²=0%, suggesting increased risk of pneumonia with use of inhaled corticosteroids in asthma patients. CONCLUSIONS Inhaled corticosteroids are associated with decreased risk of incident pneumonia in patients with asthma based on meta-analysis of available randomized trials. Although observational studies in similar patients suggested higher risk of pneumonia, the inherent methodological limitations confer lower grade of confidence in these studies.
Collapse
Affiliation(s)
- Vikas Bansal
- Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville, FL
| | - Muhammad A Mangi
- Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville, FL
| | | | - Emir Festic
- Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville, FL.
| |
Collapse
|
28
|
Karnatovskaia LV, Johnson MM, Dockter TJ, Gajic O. Perspectives of physicians and nurses on identifying and treating psychological distress of the critically ill. J Crit Care 2016; 37:106-111. [PMID: 27676170 DOI: 10.1016/j.jcrc.2016.09.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Revised: 08/22/2016] [Accepted: 09/09/2016] [Indexed: 11/28/2022]
Abstract
PURPOSE Survivors of critical illness are frequently unable to return to their premorbid level of psychocognitive functioning following discharge. Therefore, we aimed to evaluate the burden of psychological trauma experienced by patients in the intensive care unit (ICU) as perceived by clinicians to assess factors that can impede its recognition and treatment in the ICU. MATERIALS AND METHODS Two distinct role-specific Web-based surveys were administered to critical care physicians and nurses in medical and surgical ICUs of 2 academic medical centers. Responses were analyzed in the domains of psychological trauma, exacerbating/mitigating factors, and provider-patient communication. RESULTS A survey was completed by 43 physicians and 55 nurses with a response rate of 62% and 37%, respectively. Among physicians, 65% consistently consider the psychological state of the patient in decision making; 77% think it is important to introduce a system to document psychological state of ICU patients; 56% would like to have more time to communicate with patients; 77% consistently spend extra time at bedside besides rounds and often hold patient's hand/reassure them. Notably, for the question about the average level of psychological stress experienced by a patient in the ICU (with 0=no stress and 100=worst stress imaginable) during initial treatment stage and by the end of the ICU stay, median assessment by both physicians and nurses was 80 for the initial stress level and 68 for the stress level by the end of the ICU stay. Among nurses, 69% always try to minimize noise and 73% actively promote patient's rest. Physicians and nurses provided multiple specific suggestions for improving ICU environment and communication. CONCLUSIONS Both physicians and nurses acknowledge that they perceive that critically ill patients experience a high level of psychological stress that persists throughout their period of illness. Improved understanding of this phenomenon is needed to design effective therapeutic interventions. Although the lack of time is identified as significant barrier to ameliorating patient's psychological stress, the majority of clinicians indicate that they attempt to provide interventions to achieve this goal.
Collapse
Affiliation(s)
- Lioudmila V Karnatovskaia
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
| | - Margaret M Johnson
- Division of Pulmonary and Department of Critical Care Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224
| | - Travis J Dockter
- Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First St SW, Rochester, MN 55905
| | - Ognjen Gajic
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905
| |
Collapse
|
29
|
May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, d'Arminio Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JAC, Boulle A, Stephan C, Miro JM, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte AD, Del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry DHU, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clin Infect Dis 2016; 62:1571-1577. [PMID: 27025828 PMCID: PMC4885653 DOI: 10.1093/cid/ciw183] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Accepted: 03/17/2016] [Indexed: 12/30/2022] Open
Abstract
The strong association of CD4 count at start of combination therapy with subsequent survival in HIV-infected patients diminished during the first 5 years of treatment. After 5 years, lower baseline CD4 counts were not associated with higher mortality. Background. CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterized. Methods. We estimated mortality rates (MRs) by time since start of ART (<0.5, 0.5–0.9, 1–2.9, 3–4.9, 5–9.9, and ≥10 years) among patients from 18 European and North American cohorts who started ART during 1996–2001. Piecewise exponential models stratified by cohort were used to estimate crude and adjusted (for sex, age, transmission risk, period of starting ART [1996–1997, 1998–1999, 2000–2001], and AIDS and human immunodeficiency virus type 1 RNA at baseline) mortality rate ratios (MRRs) by CD4 count at start of ART (0–49, 50–99, 100–199, 200–349, 350–499, ≥500 cells/µL) overall and separately according to time since start of ART. Results. A total of 6344 of 37 496 patients died during 359 219 years of follow-up. The MR per 1000 person-years was 32.8 (95% confidence interval [CI], 30.2–35.5) during the first 6 months, declining to 16.0 (95% CI, 15.4–16.8) during 5–9.9 years and 14.2 (95% CI, 13.3–15.1) after 10 years’ duration of ART. During the first year of ART, there was a strong inverse association of CD4 count at start of ART with mortality. This diminished over the next 4 years. The adjusted MRR per CD4 group was 0.97 (95% CI, .94–1.00; P = .054) and 1.02 (95% CI, .98–1.07; P = .32) among patients followed for 5–9.9 and ≥10 years, respectively. Conclusions. After surviving 5 years of ART, the mortality of patients who started ART with low baseline CD4 count converged with mortality of patients with intermediate and high baseline CD4 counts.
Collapse
Affiliation(s)
- Margaret T May
- Schoolof Social and Community Medicine, University of Bristol, United Kingdom
| | | | - Adam Trickey
- Schoolof Social and Community Medicine, University of Bristol, United Kingdom
| | - Niels Obel
- Department of Infectious Diseases, Copenhagen University Hospital, Denmark
| | - Peter Reiss
- Department of Global Health, Academic Medical Center, University of Amsterdam, and Amsterdam Institute of Global Health and Development HIV Monitoring Foundation.,Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity-Amsterdam, Academic Medical Center, The Netherlands
| | - Fabrice Bonnet
- Bordeaux University, ISPED, INSERM U897.,CHU de Bordeaux
| | - Murielle Mary-Krause
- Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France
| | - Hasina Samji
- Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
| | - Matthias Cavassini
- Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Switzerland
| | | | - Leah C Shepherd
- Research Department of Infection and Population Health, University College London Medical School, United Kingdom
| | - Heidi M Crane
- Center for AIDS Research, University of Washington, Seattle
| | | | - Greer A Burkholder
- Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham
| | - Margaret M Johnson
- Department of HIV Medicine, Royal Free London NHS Foundation Trust, United Kingdom
| | - Paz Sobrino-Vegas
- Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid
| | - Pere Domingo
- Department of Medicine, Autonomous University of Barcelona, Spain
| | | | - Amy C Justice
- Yale University School of Medicine, New Haven.,Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut
| | | | - José M Miró
- Hospital Clinic-IDIBAPS, University of Barcelona, Spain
| | - Jonathan A C Sterne
- Schoolof Social and Community Medicine, University of Bristol, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Karnatovskaia LV, Johnson MM, Benzo RP, Gajic O. The spectrum of psychocognitive morbidity in the critically ill: A review of the literature and call for improvement. J Crit Care 2015; 30:130-7. [DOI: 10.1016/j.jcrc.2014.09.024] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Revised: 09/07/2014] [Accepted: 09/29/2014] [Indexed: 10/24/2022]
|
31
|
Karnatovskaia LV, Khoor A, Johnson MM, Kaplan J. A 60-year-old woman with PET scan-avid lung nodules and a history of a ruptured silicone breast implant. Chest 2014; 146:e138-e142. [PMID: 25288007 DOI: 10.1378/chest.14-0203] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
A 60-year-old woman was referred to the pulmonary clinic for evaluation of lung nodules. Her medical history was notable for hypothyroidism, anxiety, and a ruptured breast implant for which incomplete surgical resection and evacuation had been performed 10 years previously. She was a lifelong nonsmoker and worked as a gym instructor. The patient denied occupational exposures and had not traveled recently. Medications included levothyroxine and alprazolam. Except for a 1-month history of occasional dry cough, the review of systems was negative. The patient's physician queried whether the previously ruptured silicone breast implant may have played a role in the genesis of the nodules and referred the patient to our institution for further management. The lack of systemic symptoms relative to the degree of lung involvement provided an early diagnostic clue.
Collapse
Affiliation(s)
| | - Andras Khoor
- Department of Pathology, Mayo Clinic Florida, Jacksonville, FL
| | - Margaret M Johnson
- Departments of Pulmonary and Critical Care Medicine, Mayo Clinic Florida, Jacksonville, FL
| | - Joseph Kaplan
- Departments of Pulmonary and Critical Care Medicine, Mayo Clinic Florida, Jacksonville, FL
| |
Collapse
|
32
|
Abstract
Pulmonary infections due to nontuberculous mycobacteria (NTM) are increasingly recognized worldwide. Although over 150 different species of NTM have been described, pulmonary infections are most commonly due to Mycobacterium avium complex (MAC), Mycobacterium kansasii, and Mycobacterium abscessus. The identification of these organisms in pulmonary specimens does not always equate with active infection; supportive radiographic and clinical findings are needed to establish the diagnosis. It is difficult to eradicate NTM infections. A prolonged course of therapy with a combination of drugs is required. Unfortunately, recurrent infection with new strains of mycobacteria or a relapse of infection caused by the original organism is not uncommon. Surgical resection is appropriate in selected cases of localized disease or in cases in which the infecting organism is resistant to medical therapy. Additionally, surgery may be required for infections complicated by hemoptysis or abscess formation. This review will summarize the practical aspects of the diagnosis and management of NTM thoracic infections, with emphasis on the indications for surgery and the results of surgical intervention. The management of NTM disease in patients with human immunodeficiency virus (HIV) infections is beyond the scope of this article and, unless otherwise noted, comments apply to hosts without HIV infection.
Collapse
Affiliation(s)
- Margaret M Johnson
- 1 Division of Pulmonary Medicine, 2 Department of Cardiothoracic Surgery, Mayo Clinic, Florida, USA
| | - John A Odell
- 1 Division of Pulmonary Medicine, 2 Department of Cardiothoracic Surgery, Mayo Clinic, Florida, USA
| |
Collapse
|
33
|
Malone JC, Ussavarungsi K, Jolles HI, Johnson MM. An Unusual Retrocardiac Density. Am J Respir Crit Care Med 2013; 188:1262. [DOI: 10.1164/rccm.201302-0360im] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
34
|
Cangemi DJ, Donovan ST, Johnson MM. 62-year-old man with painless jaundice and hyponatremia. Mayo Clin Proc 2013; 88:e49-53. [PMID: 23726406 DOI: 10.1016/j.mayocp.2012.09.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2012] [Revised: 09/13/2012] [Accepted: 09/20/2012] [Indexed: 11/22/2022]
Affiliation(s)
- David J Cangemi
- Resident in Internal Medicine, Mayo School of Graduate Medical Education, Jacksonville, FL 32224, USA.
| | | | | |
Collapse
|
35
|
Arunthari V, Bruinsma RS, Lee AS, Johnson MM. A Prospective, Comparative Trial of Standard and Breath-Actuated Nebulizer: Efficacy, Safety, and Satisfaction. Respir Care 2012; 57:1242-7. [DOI: 10.4187/respcare.01450] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
36
|
Abstract
The distinction between oncocytoma and chromophobe renal cell carcinoma, important clinically, may be challenging, especially as the tissue sample size decreases. Ancillary studies can be helpful, although subject to interpretation and sample variability. The aim of this study was to examine the value of electron microscopy in differentiating between oncocytoma and chromophobe renal cell carcinoma on formalin fixed paraffin embedded needle core biopsies. Twenty renal needle core biopsies were evaluated. Despite formalin fixation and paraffin embedding, the classic ultrastructural features of these neoplasms were retained, revealing 80% sensitivity and 100% specificity by initial work-up.
Collapse
Affiliation(s)
- N B Johnson
- Beth Israel Deaconess Medical Center, Department of Pathology, Boston, MA 02114, USA
| | | | | | | |
Collapse
|
37
|
Affiliation(s)
- John E. Moss
- Resident in Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic Florida, Jacksonville, FL
| | - Michael J. Maniaci
- Resident in Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic Florida, Jacksonville, FL
| | - Margaret M. Johnson
- Adviser to residents and Consultant in Pulmonary Medicine, Mayo Clinic Florida, Jacksonville, FL
- Individual reprints of this article are not available. Address correspondence to Margaret M. Johnson, MD, Division of Pulmonary Medicine, Mayo Clinic Florida, 4500 San Pablo Rd, Jacksonville, FL 32224 ()
| |
Collapse
|
38
|
Freeman WD, Barrett KM, Biewend ML, Johnson MM, Divertie GD, Meschia JF. Predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest. Neurology 2009; 73:997-8; author reply 998. [PMID: 19770479 DOI: 10.1212/wnl.0b013e3181af0c42] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
39
|
Gisel JJ, Brumble LM, Johnson MM. Bordetella bronchiseptica pneumonia in a kidney-pancreas transplant patient after exposure to recently vaccinated dogs. Transpl Infect Dis 2009; 12:73-6. [PMID: 19874567 DOI: 10.1111/j.1399-3062.2009.00451.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Bordetella bronchiseptica is an uncommon cause of respiratory infection in humans generally occurring in immunocompromised individuals exposed to infected animals. A 61-year-old female underwent a kidney-pancreas transplant 7 years before presentation. Postoperative immunosuppression was achieved with sirolimus and mycophenolate mofetil. The patient was doing well until she developed a small bowel obstruction secondary to adhesions. She underwent surgical adhesiolysis without complications. Two weeks postoperatively the patient developed pneumonia. She failed to respond to repeated courses of antibiotics, and thus, diagnostic bronchoscopy with bronchoalveolar lavage (BAL) was performed. BAL cultures grew B. bronchiseptica. Further investigation revealed that the patient's dogs had recently received a live-attenuated B. bronchiseptica intranasal vaccination. The patient recovered after 21 days of therapy with doxycycline based upon in vitro susceptibility testing. B. bronchiseptica is an uncommon but recognized human pathogen. It most commonly affects immunocompromised individuals. Here, we report a culture-proven case of B. bronchiseptica pneumonia in an immunocompromised host residing in a household with her dogs who had recently received live-attenuated, intranasal B. bronchiseptica vaccinations. As polymerase chain reaction testing was not performed comparing the isolated strain to the vaccination strain, the association is presumptive. This report expands the spectrum of immunocompromised hosts to include renal-pancreas transplant patients who have developed infection from B. bronchiseptica, while illustrating the risks associated with animal contacts and attenuated vaccines in the immunosuppressed population.
Collapse
Affiliation(s)
- J J Gisel
- Pulmonary and Critical Care Division, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA.
| | | | | |
Collapse
|
40
|
Albarracin CT, Sigauke E, Whitman G, Yang WT, Resetkova E, Johnson MM, Nguyen CV, Sneige N. Atypical and columnar cell lesions in breast needle biopsies for indeterminate microcalcifications: predictors of higher risk findings requiring surgical excision. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3004
Background: Columnar cell lesions (CCL) are frequently identified in biopsies performed for calcifications. The primary objective of this study is to identify histologic features of CCL in directional vacuum-assisted needle biopsies (DVAB) that could predict a higher risk lesion requiring excision.
 Design: From June 2002 to January 2008, we retrieved the materials for 88 DVABs and their subsequent segmental resections. We excluded carcinomas, intraductal papillomas, fibroadenomas, adenosis, or radial scars. Using World Health Organization criteria, CCLs were classified as CCL with no atypia (CCL-NA), CCL with cytologic atypia (CCL-CA; flat epithelial atypia), or architectural atypia/atypical ductal hyperplasia (CCL-ADH) in the background of CCL. In cases with atypia, the involved terminal duct lobular units/ducts (TDLUs) were quantified. Atypical cases were separated two groups as follows: minimal ADH (≤2 TDLU and minimal cytologic atypia) and extensive ADH/borderline DCIS (≥3 TDLU and/or significant cytologic atypia bordering on DCIS).Radiographs were evaluated to assess amount of calcifications removed. Biopsy results were correlated with the subsequent surgical excision results.
 Results: Eight of 88 biopsies were excluded because of overdiagnosis or because the lesions were not associated with microcalcifications. The remaining 80 biopsies included 5 cases of CCL-NA, 4 pure CCL-CA, 20 mixed CCL-CA + ADH and 51 pure CCL-ADH. Microcalcifications were identified in association with the targeted lesions. There were no higher risk findings in any of the resection specimens with CCL-NA and pure CCL-CA. Ten of the atypical lesions showed carcinoma on excision (9 DCIS and 1 invasive cancer). Twenty-five percent (9/36) extensive ADH/borderline DCIS showed carcinoma on excision. In contrast, only 2.5% (1/39) of minimal ADH cases showed carcinoma on excision. Radiologic review revealed residual abnormality in this one case.
 Conclusion: In summary, the extent of lobular involvement by atypia (CCL-CA or CCL-ADH) correlated with the presence or absence of higher risk lesions upon subsequent excision. These results suggest that additional surgery may not be necessary for CCL-CA or CCL-ADH that is limited to ≤ 2 foci provided sampling of the microcalcifications is adequate.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3004.
Collapse
Affiliation(s)
- CT Albarracin
- 1 Pathology, Diagnostic Radiology, and Quantitative Science, University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - E Sigauke
- 1 Pathology, Diagnostic Radiology, and Quantitative Science, University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - G Whitman
- 1 Pathology, Diagnostic Radiology, and Quantitative Science, University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - WT Yang
- 1 Pathology, Diagnostic Radiology, and Quantitative Science, University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - E Resetkova
- 1 Pathology, Diagnostic Radiology, and Quantitative Science, University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - MM Johnson
- 1 Pathology, Diagnostic Radiology, and Quantitative Science, University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - CV Nguyen
- 1 Pathology, Diagnostic Radiology, and Quantitative Science, University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - N Sneige
- 1 Pathology, Diagnostic Radiology, and Quantitative Science, University of Texas M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
41
|
Berry DA, Ueno NT, Johnson MM, Lei X, Smith DA, Caputo J, Yancey LJ, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-6113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #6113
Background: The role of high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation for metastatic breast cancer has not been well defined. The statistical power of the available trials has limited precision for determining whether HDC has any benefit for this indication, or for any subset of patients.
 Methods: Individual patient data from the 6 known randomized trials were merged into a single database. The primary endpoint was overall survival (OS): time from randomization to death. The secondary endpoint was progression-free survival (PFS). Cox proportional hazards regression compared the effect of HDC vs standard-dose chemotherapy (SDC) on PFS and OS adjusted for age, trial and hormone receptor (HmR) status (positive if either estrogen (ER) or progesterone (PgR) receptor positive), and other variables. Among the subset analyses considered were by age, HmR status, number metastatic sites, and soft tissue metastases.
 Results: A total of 846 patients (433 HDC, 413 SDC) had median follow-up of 1.9 years. Median age was 47 years (range 23 to 65). Preliminary analyses show that after adjusting for age and trial, HDC significantly prolonged OS (hazard ratio (HR) 0.86; 95%CI 0.73-1.00; p=0.05) and PFS (HR 0.73; 95%CI 0.63-0.84; p<0.0001). Mean improvement (out to 8 yrs) was 4 months for both OS and PFS. Both age (p=0.023) and soft tissue disease (p=0.0025) had statistically significant interactions with treatment for OS, but neither remain significant after adjusting for multiple comparisons.
 Conclusions: HDC may have a modest benefit on OS that may be greater in patients younger than 50 years. However, we were not able to draw firm conclusions about age or other subset analyses.
 

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6113.
Collapse
Affiliation(s)
- DA Berry
- 1 MDACC-EBMT Meta-Analysis Group, Houston, TX
| | - NT Ueno
- 1 MDACC-EBMT Meta-Analysis Group, Houston, TX
| | - MM Johnson
- 1 MDACC-EBMT Meta-Analysis Group, Houston, TX
| | - X Lei
- 1 MDACC-EBMT Meta-Analysis Group, Houston, TX
| | - DA Smith
- 1 MDACC-EBMT Meta-Analysis Group, Houston, TX
| | - J Caputo
- 1 MDACC-EBMT Meta-Analysis Group, Houston, TX
| | - LJ Yancey
- 1 MDACC-EBMT Meta-Analysis Group, Houston, TX
| | - M Bregni
- 1 MDACC-EBMT Meta-Analysis Group, Houston, TX
| | - T Demirer
- 1 MDACC-EBMT Meta-Analysis Group, Houston, TX
| |
Collapse
|
42
|
Wallace MB, Pascual JMS, Raimondo M, Woodward TA, McComb BL, Crook JE, Johnson MM, Al-Haddad MA, Gross SA, Pungpapong S, Hardee JN, Odell JA. Minimally invasive endoscopic staging of suspected lung cancer. JAMA 2008; 299:540-6. [PMID: 18252884 DOI: 10.1001/jama.299.5.540] [Citation(s) in RCA: 260] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
CONTEXT In patients with suspected lung cancer, the presence of mediastinal lymph node metastasis is a critical determinant of therapy and prognosis. Invasive staging with pathologic confirmation is recommended. Many methods for staging exist; mediastinoscopy, an invasive procedure requiring general anesthesia, is currently regarded as the diagnostic standard. OBJECTIVE To compare the diagnostic accuracy of 3 methods of minimally invasive endoscopic staging (and their combinations): traditional transbronchial needle aspiration (TBNA), endobronchial ultrasound-guided fine-needle aspiration (EBUS-FNA), and transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). In particular, we aimed to compare EBUS-FNA with TBNA. DESIGN, SETTING, AND PARTICIPANTS Invasive staging of the mediastinum among consecutive patients with suspected lung cancer at a US academic medical center from November 2004 through October 2006. INTERVENTION TBNA, EBUS-FNA, and EUS-FNA performed sequentially as a single combined procedure. MAIN OUTCOME MEASURE Sensitivity for detecting mediastinal lymph node metastases, using pathologic confirmation and 6- to 12-month clinical follow-up as the criterion standard. RESULTS Among 138 patients who met all study criteria, 42 (30%) had malignant lymph nodes. EBUS-FNA was more sensitive than TBNA, detecting 29 (69%) vs 15 (36%) malignant lymph nodes (P = .003). The combination of EUS-FNA and EBUS-FNA (EUS plus EBUS) had higher estimated sensitivity (93% [39/42]; 95% confidence interval, 81%-99%) and negative predictive value (97% [96/99]; 95% confidence interval, 91%-99%) compared with either method alone. EUS plus EBUS also had higher sensitivity and higher negative predictive value for detecting lymph nodes in any mediastinal location and for patients without lymph node enlargement on chest computed tomography. CONCLUSIONS These findings suggest that EBUS-FNA has higher sensitivity than TBNA and that EUS plus EBUS may allow near-complete minimally invasive mediastinal staging in patients with suspected lung cancer. These results require confirmation in other studies but suggest that EUS plus EBUS may be an alternative approach for mediastinal staging in patients with suspected lung cancer.
Collapse
Affiliation(s)
- Michael B Wallace
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida 32224, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Wallace MB, Pascual J, Raimondo M, Woodward TA, McComb B, Crook J, Johnson MM, Al-Haddad MA, Gross SA, Hardee J, Odell J. ENDOSCOPIC ULTRASOUND, ENDOBRONCHIAL ULTRASOUND, AND BRONCHOSCOPIC FINE NEEDLE ASPIRATION FOR THE STAGING OF SUSPECTED LUNG CANCER. Chest 2007. [DOI: 10.1378/chest.132.4_meetingabstracts.470b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
44
|
Festic E, Abraham PJ, Burnett OL, Young PM, Johnson MM. Increased radiotracer uptake on positron emission tomography after invasive thoracic procedures: a case series. Mayo Clin Proc 2007; 82:1060-4. [PMID: 17803872 DOI: 10.4065/82.9.1060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To investigate the hypothesis that tissue changes induced by invasive thoracic procedures may be associated with increased fluorine 18-labeled fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) scans, potentially leading to these tissue changes being mistaken for malignancies. PATIENTS AND METHODS We retrospectively reviewed the records of all patients undergoing bronchoscopies and FDG-PET at Mayo Clinic Jacksonville from February 2002 to September 2004 and identified patients who had undergone computed tomography (CT) of the chest and bronchoscopy before FDG-PET. We identified and reviewed the imaging studies of patients who had increased FDG uptake on PET scans and whose CT scans showed no corresponding abnormalities suggestive of malignancy. RESULTS Eighty-one patients had undergone both bronchoscopy and PET within the defined study period. Of these, 45 (56%) underwent PET within 4 weeks after bronchoscopy, and 13 (29%) of these 45 patients had increased FDG uptake on PET scans that did not correlate with pathological findings on CT. We judged that increased uptake on 3 (23%) of the 13 PET scans was most likely related to the bronchoscopic procedure. Additionally, 2 patients who had undergone thoracoscopy after bronchoscopy but before PET had discordant CT and PET findings. CONCLUSION Invasive thoracic procedures may cause an increased uptake of radiotracer on PET scans that could be mistakenly interpreted as evidence of malignancy. To avoid clinical misjudgment, clinicians should perform PET before invasive thoracic procedures.
Collapse
Affiliation(s)
- Emir Festic
- Division of Pulmonary Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
| | | | | | | | | |
Collapse
|
45
|
Bloomfield EL, Divertie GD, Burger CD, Larson JS, Brown DR, Patel BM, Rady MY, Johnson MM, Murray MJ. A comparison of intensive care unit physician staffing costs at the 3 Mayo Clinic sites. Mayo Clin Proc 2006; 81:1457-61. [PMID: 17120401 DOI: 10.4065/81.11.1457] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES To determine the provider cost of administering intensive care unit (ICU) services, comparing 3 different staffing models for ICU coverage, and to compare the costs of using house staff vs nonphysician providers (NPPs). METHODS Data were collected on total staff composition and number of beds In ICUs from January 1, 2004, through December 31, 2004, at the 3 Mayo Clinic sites: Rochester, Minn; Jacksonville, Fla; and Scottsdale, Ariz. Institutional or national average staff salaries were used to determine total staffing costs per ICU bed per year at each site. Medicare medical education reimbursements were also taken into account. RESULTS Costs per ICU bed for physician staffing were $18,630 in Rochester, $37,515 in Jacksonville, and $38,010 in Scottsdale. When NPPs were substituted for house staff, the costs per bed were $72,466 in Rochester, $61,291 in Jacksonville, and $49,909 in Scottsdale. Incremental costs per ICU bed using NPPs were $53,836 in Rochester, $23,776 in Jacksonville, and $11,899 in Scottsdale. CONCLUSION Use of residents and fellows in ICU staffing at a major tertiary health center is more cost-efficient than use of NPPs. This finding could have Implications for the cost of physician services in nonteaching community hospitals and the methods by which care is provided.
Collapse
Affiliation(s)
- Eric L Bloomfield
- Department of Critical Care, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL 32224, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
Nontuberculous mycobacteria (NTM) are increasingly recognized as important pulmonary pathogens. Mycobacterium avium intracellulare complex (MAC) causes most lung infections due to NTM. Patients with preexisting lung disease or immunodeficiency are at greatest risk for developing MAC infection. The majority of MAC pulmonary cases, however, occur in immunocompetent elderly women in association with nodular infiltrates and bronchiectasis. More recently, pulmonary disease has also been described in immunocompetent patients after exposure to MAC-contaminated hot tubs. We describe a case of aggressive MAC lung disease in a young immunocompetent female patient without preexisting lung disease whose clinical and pathologic characteristics do not fit into any of these categories and may represent a unique manifestation of MAC lung disease.
Collapse
Affiliation(s)
- E Andrew Waller
- Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, Department of Pulmonary Medicine, 4500 San Pablo Rd, Jacksonville, FL 32224, USA.
| | | | | | | | | | | |
Collapse
|
47
|
Marrer E, Satoh AT, Johnson MM, Piddock LJV, Page MGP. Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin. Antimicrob Agents Chemother 2006; 50:269-78. [PMID: 16377697 PMCID: PMC1346767 DOI: 10.1128/aac.50.1.269-278.2006] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Streptococcus pneumoniae M22 is a multidrug-resistant mutant selected after exposure of capsulated wild-type S. pneumoniae NCTC 7465 (strain M4) to ciprofloxacin. DNA microarray analysis comparing the gene expression profiles of strain M22 with those of strain M4 showed that strain M22 constitutively expressed 22 genes at levels higher than those observed in strain M4 under all conditions studied. These included the genes encoding the enzymes involved in branched-chain amino acid biosynthesis and two genes (patA and patB) with sequences suggestive of ABC transporter proteins. Expression of the patA and patB genes was induced by ciprofloxacin in both strains, but in strain M4 it only reached the levels observed in strain M22 after long incubation with high concentrations of ciprofloxacin. The altered expression profile observed with strain M22 suggested that the mutation or mutations acquired during resistance selection bring the cell into a state in which the expression of critical genes is preemptively altered to correct for the potential effects of ciprofloxacin on gene expression in the parent strain.
Collapse
Affiliation(s)
- Estelle Marrer
- The University of Texas Health Science Center at San Antonio, Texas 78229-3900, USA
| | | | | | | | | |
Collapse
|
48
|
Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 2006; 25:3956-62. [PMID: 16474847 DOI: 10.1038/sj.onc.1209419] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Activating mutations of the genes for NRAS and BRAF, components of the p44/42 mitogen-activated protein kinase (MAPK) pathway, are common findings in melanoma. Recent evidence in several nonmelanoma cell systems supports the regulation of the inducible nitric oxide synthase (iNOS) gene by this pathway. On the basis of our data showing that melanoma iNOS expression predicts shortened patient survival, we formulated the hypothesis that activating mutations of NRAS or BRAF, which lead to constitutive activation of the p44/42 MAPK pathway, drive iNOS expression in human melanoma. In the present study, we have shown that inhibition of melanoma iNOS activity by S-methylisothiourea leads to decreased cell proliferation, confirming the importance of iNOS activity for melanoma cell growth. Regulation of melanoma iNOS expression by the p44/42 MAPK pathway was demonstrated by inhibition of the pathway by U0126, and by BRAF RNA interference. To explore this regulatory pathway in human tissue, 20 melanoma tumors were examined for NRAS and BRAF mutations, immunohistochemical evidence of ERK phosphorylation, and iNOS expression. A significant association was found among these three features. We conclude that in human melanoma, activating mutations of NRAS and BRAF drive constitutive iNOS expression and, implicitly, nitric oxide production, contributing to the poor survival of these patients.
Collapse
Affiliation(s)
- J A Ellerhorst
- The Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, 77030, USA.
| | | | | | | | | | | |
Collapse
|
49
|
Festic E, Johnson MM, Johnson MM. The Safety and Efficacy of Topical Cocaine in Flexible Fiberoptic Bronchoscopy. Chest 2004. [DOI: 10.1378/chest.126.4_meetingabstracts.818s-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
50
|
McDermott PF, Bodeis SM, Aarestrup FM, Brown S, Traczewski M, Fedorka-Cray P, Wallace M, Critchley IA, Thornsberry C, Graff S, Flamm R, Beyer J, Shortridge D, Piddock LJ, Ricci V, Johnson MM, Jones RN, Reller B, Mirrett S, Aldrobi J, Rennie R, Brosnikoff C, Turnbull L, Stein G, Schooley S, Hanson RA, Walker RD. Development of a Standardized Susceptibility Test forCampylobacterwith Quality-Control Ranges for Ciprofloxacin, Doxycycline, Erythromycin, Gentamicin, and Meropenem. Microb Drug Resist 2004; 10:124-31. [PMID: 15256027 DOI: 10.1089/1076629041310064] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
A standardized agar dilution susceptibility testing method was developed for Campylobacter that consisted of testing on Mueller-Hinton medium supplemented with 5% defibrinated sheep blood in an atmosphere of 10% CO2, 5% O2, and 85% N2. Campylobacter jejuni ATCC 33560 was identified as a quality-control (QC) strain. Minimal inhibitory concentration (MIC) QC ranges were determined for two incubation time/temperature combinations: 36 degrees C for 48 hr and 42 degrees C for 24 hr. Quality-control ranges were determined for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. For all antimicrobial agents tested at both temperatures, 95-100% of the QC MIC results fell within recommended QC ranges. Twenty-one Campylobacter clinical isolates, encompassing five species of Campylobacter (C. jejuni, C. coli, C. jejuni, subsp. doylei, C. fetus, and C. lari) were tested in conjunction with the C. jejuni QC strain. While C. jejuni and C. coli could be reliably tested under both test conditions, growth of C. jejuni subsp. doylei, C. fetus, and C. lari isolates was inconsistent when incubated at 42 degrees C. Therefore, it is recommended that these species only be tested at 36 degrees C.
Collapse
Affiliation(s)
- P F McDermott
- Office of Research, Center for Veterinary Medicine, US Food and Drug Administration, Laurel, MD 20708, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|